Ami Fadia
Stock Analyst at Needham
(4.59)
# 240
Out of 5,113 analysts
380
Total ratings
53.64%
Success rate
28.13%
Average return
Main Sectors:
Stocks Rated by Ami Fadia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $210 → $235 | $166.35 | +41.27% | 35 | Jan 12, 2026 | |
| GHRS GH Research | Maintains: Buy | $19 → $29 | $16.60 | +74.70% | 3 | Jan 6, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $154 → $169 | $184.52 | -8.41% | 18 | Dec 31, 2025 | |
| COGT Cogent Biosciences | Reiterates: Hold | n/a | $37.86 | - | 24 | Dec 8, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $304 → $315 | $294.04 | +7.13% | 16 | Dec 8, 2025 | |
| HRMY Harmony Biosciences Holdings | Reiterates: Buy | $42 | $37.36 | +12.42% | 39 | Nov 24, 2025 | |
| DAWN Day One Biopharmaceuticals | Reiterates: Buy | $16 | $12.03 | +33.00% | 22 | Nov 24, 2025 | |
| RVMD Revolution Medicines | Maintains: Buy | $66 → $72 | $97.78 | -26.37% | 27 | Nov 6, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $28 → $29 | $26.86 | +7.97% | 12 | Nov 6, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $170 → $184 | $134.51 | +36.79% | 16 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $44 | $33.11 | +32.89% | 4 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $2.04 | +292.16% | 10 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $21.57 | - | 37 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $3.90 | +207.69% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 | $5.22 | +110.73% | 20 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $173.12 | - | 43 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $25.73 | +36.03% | 1 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $29 | $7.00 | +314.29% | 21 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $240 → $320 | $15.55 | +1,957.88% | 2 | Feb 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $63 → $75 | $20.50 | +265.85% | 7 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $23 | $0.34 | +6,606.41% | 4 | Oct 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $64 → $63 | $14.40 | +337.50% | 5 | Sep 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $32.14 | - | 9 | Oct 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $1.44 | +1,427.78% | 4 | Jan 3, 2018 |
Jazz Pharmaceuticals
Jan 12, 2026
Maintains: Buy
Price Target: $210 → $235
Current: $166.35
Upside: +41.27%
GH Research
Jan 6, 2026
Maintains: Buy
Price Target: $19 → $29
Current: $16.60
Upside: +74.70%
Axsome Therapeutics
Dec 31, 2025
Maintains: Buy
Price Target: $154 → $169
Current: $184.52
Upside: -8.41%
Cogent Biosciences
Dec 8, 2025
Reiterates: Hold
Price Target: n/a
Current: $37.86
Upside: -
Praxis Precision Medicines
Dec 8, 2025
Maintains: Buy
Price Target: $304 → $315
Current: $294.04
Upside: +7.13%
Harmony Biosciences Holdings
Nov 24, 2025
Reiterates: Buy
Price Target: $42
Current: $37.36
Upside: +12.42%
Day One Biopharmaceuticals
Nov 24, 2025
Reiterates: Buy
Price Target: $16
Current: $12.03
Upside: +33.00%
Revolution Medicines
Nov 6, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $97.78
Upside: -26.37%
ACADIA Pharmaceuticals
Nov 6, 2025
Maintains: Buy
Price Target: $28 → $29
Current: $26.86
Upside: +7.97%
Neurocrine Biosciences
Oct 29, 2025
Maintains: Buy
Price Target: $170 → $184
Current: $134.51
Upside: +36.79%
Oct 29, 2025
Maintains: Buy
Price Target: $43 → $44
Current: $33.11
Upside: +32.89%
Oct 28, 2025
Maintains: Buy
Price Target: $6 → $8
Current: $2.04
Upside: +292.16%
Oct 22, 2025
Downgrades: Hold
Price Target: n/a
Current: $21.57
Upside: -
Oct 13, 2025
Initiates: Buy
Price Target: $12
Current: $3.90
Upside: +207.69%
Sep 30, 2025
Reiterates: Buy
Price Target: $11
Current: $5.22
Upside: +110.73%
Sep 24, 2025
Reiterates: Hold
Price Target: n/a
Current: $173.12
Upside: -
May 28, 2025
Initiates: Buy
Price Target: $35
Current: $25.73
Upside: +36.03%
May 2, 2025
Reiterates: Buy
Price Target: $29
Current: $7.00
Upside: +314.29%
Feb 1, 2021
Maintains: Outperform
Price Target: $240 → $320
Current: $15.55
Upside: +1,957.88%
Jan 21, 2021
Downgrades: Market Perform
Price Target: $63 → $75
Current: $20.50
Upside: +265.85%
Oct 1, 2020
Maintains: Market Perform
Price Target: $15 → $23
Current: $0.34
Upside: +6,606.41%
Sep 17, 2020
Maintains: Outperform
Price Target: $64 → $63
Current: $14.40
Upside: +337.50%
Oct 1, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $32.14
Upside: -
Jan 3, 2018
Initiates: Outperform
Price Target: $22
Current: $1.44
Upside: +1,427.78%